A. Fekkar
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Fekkar.
BMC Infectious Diseases | 2015
Simon Garinet; Jérôme Tourret; Stéphane Barete; Nadia Arzouk; Isabelle Meyer; C. Francès; Annick Datry; Dominique Mazier; Benoit Barrou; A. Fekkar
BackgroundNeoscytalidium species (formerly Scytalidium species) are black fungi that usually cause cutaneous infections mimicking dermatophytes lesions. Very few publications have reported invasive or disseminated infections.Case presentationIn this paper, we report the clinical presentations, treatments and outcomes of five cases of invasive Neoscytalidium infections with cutaneous involvement, including two cases with disseminated infection, in five renal transplant recipients. To our knowledge, this is the first report of a series—albeit small—of renal transplant patients in whom this infection was identified. All cases occurred in a single hospital in Paris, France, between 2001 and 2011. Patients all originate from tropical area.ConclusionTreatments of Neoscytalidium infection varied greatly, underlining the lack of a recommendation for a standardized treatment. All patients were cured after long-term antifungal therapy and/or surgical excision. Interestingly, one patient with disseminated infection involving the left elbow, the right leg, the lungs and the nasal septum was cured by medical therapy only without surgery. This may suggest that in contrast to others mycoses (such as mucormycosis), an adequate medical treatment could be sufficient for treating Neoscytalidium. We also point out the difficulties we had in diagnosing two patients with Kaposi’s sarcoma because of the similarity of the lesions. Furthermore, our report underlines the need to check for this rare infection in immunocompromised kidney transplant recipients originating from tropical areas.
Virulence | 2017
Sarah Sze Wah Wong; Orhan Rasid; Paris Laskaris; A. Fekkar; Jean-Marc Cavaillon; William J. Steinbach; Oumaïma Ibrahim-Granet
ABSTRACT Cyclosporin A (CsA) is widely used as an immunosuppressive agent for organ transplant recipients. CsA inhibits calcineurin, which is highly conserved in mammals and fungi, and thus affects both types of organism. In mammals, the immunosuppressive effect of CsA is via hampering T cell activation. In fungi, the growth inhibitory effect of CsA is via interference with hyphal growth. The aim of this study was to determine whether CsA renders mice susceptible to invasive pulmonary aspergillosis (IPA) and whether it can protect immunosuppressed mice from infection. We therefore examined both the antifungal and the immunosuppressive activity of CsA in immunosuppressed and in immunocompetent mice infected with Aspergillus fumigatus to model IPA. We found that daily injections of CsA could not produce an antifungal effect sufficient to rescue immunosuppressed mice from lethal IPA. However, a 100% survival rate was obtained in non-immunosuppressed mice receiving daily CsA, indicating that CsA did not render the mice vulnerable to IPA. The lymphocyte subset was significantly suppressed by CsA, while the myeloid subset was not. Therefore, we speculate that CsA does not impair the host defense against IPA since the myeloid cells are preserved.
Parasite | 2015
Oussama Mouri; Eric Kendjo; Feriel Touafek; A. Fekkar; Ousmane Konte; Sébastien Imbert; Régis Courtin; Dominique Mazier; Luc Paris
Determining specific immune status against Toxoplasma gondii is essential for assessing the risk of reactivation in immunocompromised patients or defining serological monitoring and appropriate prophylactic measures during pregnancy. In France, toxoplasmosis serological screening requires systematic testing for IgM and IgG antibodies. The Platelia Toxo IgG and IgM test (Bio-Rad) is one of the most widely used tests for anti-toxoplasmic antibody detection. We performed a study on 384 sera, including 123 IgG negative (<6 IU/mL) and 261 IgG equivocal (6–9 IU/mL) sera tested with Platelia Toxo IgG and collected during routine screening at Pitié-Salpêtrière Hospital, Paris, France to determine the best-performing IgG titer cut-off value. Out of these 383 sera, 298 were IgM negative by Platelia Toxo IgM and 86 were IgM positive. All sera were also tested against Toxo IgG II LD BIO western blot test as confirmation. Our results indicated that an IgG titer cut-off value of ≥4.4 IU/mL for the Platelia Toxo IgG met the definition of positivity, a value significantly lower than that indicated by the manufacturers. In the presence of IgM antibodies, the IgG titer cut-off decreased significantly to a value ≥0.2 IU/mL. This latter cut-off also allowed adequate diagnosis of proven toxoplasmosis seroconversion in 76.7% of cases (33/43). Our findings may improve toxoplasmosis care by reducing therapeutic intervention time and eliminating the need for further serological monitoring.
Clinical Microbiology and Infection | 2017
Sébastien Imbert; Jean-Yves Brossas; Martine Palous; Isabelle Joly; Isabelle Meyer; A. Fekkar
OBJECTIVES Cerebral aspergillosis is a rare but often fatal form of invasive aspergillosis that remains difficult to diagnose. The literature has shown the value of Aspergillus PCR in blood-derived samples for the diagnosis of invasive aspergillosis but provides far less information for cerebrospinal fluid (CSF) in cerebral aspergillosis. Here, we evaluated the usefulness of an Aspergillus PCR assay performed on CSF for the diagnosis of cerebral aspergillosis. METHODS This retrospective study involved 72 patients with suspected cerebral aspergillosis for a total of 88 CSF samples in whom CSF Aspergillus PCR was performed. RESULTS Seventeen patients had proven/probable invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria, including 12 cases of proven/probable cerebral aspergillosis. Aspergillus PCR in CSF was positive in nine of the twelve patients with cerebral aspergillosis, i.e. 75% sensitivity. In contrast, CSF culture was positive for Aspergillus in only two patients. In the non-cerebral aspergillosis group (60 patients), PCR was positive in one patient, i.e. 98.3% specificity. In this particular population of high-risk patients with suspicion of cerebral aspergillosis, the disease incidence was 16.7%. Therefore, the positive and negative predictive values of PCR were 90% and 95.2%, respectively. CONCLUSION The results of this study indicate that Aspergillus PCR in CSF is an interesting tool that may eliminate the need for cerebral biopsy in patients with suspected cerebral aspergillosis.
Clinical Microbiology and Infection | 2016
Sébastien Imbert; Lauraine Gauthier; Isabelle Joly; Jean-Yves Brossas; Madalina Uzunov; Feriel Touafek; Sophie Brun; Dominique Mazier; Annick Datry; A. Fekkar
Journal of Antimicrobial Chemotherapy | 2014
J. Lescar; I. Meyer; K. Akshita; Kannan Srinivasaraghavan; Chandra Verma; M. Palous; Dominique Mazier; A. Datry; A. Fekkar
The Journal of Allergy and Clinical Immunology | 2016
Sébastien Imbert; Priscillia Bresler; Alexandre Boissonnas; Lauraine Gauthier; Laetitia Souchet; Madalina Uzunov; Véronique Leblond; Dominique Mazier; Stéphanie Nguyen; A. Fekkar
Clinical Microbiology and Infection | 2016
S. Imbert; A. Pons; S. Jacob; I. Meyer; M. Palous; Corinne Vezinet; Olivier Langeron; C. Hennequin; Antoine Monsel; A. Fekkar
BMC Infectious Diseases | 2017
Jérôme Tourret; N. Benabdellah; S. Drouin; F. Charlotte; J. Rottembourg; N. Arzouk; A. Fekkar; Benoit Barrou
Journal De Mycologie Medicale | 2016
A. Fekkar; L. Castain; A. Pons; I. Meyer; Martine Palous; C. Vezinet; Dominique Mazier; O. Langeron; C. Hennequin; A. Monsel; Sébastien Imbert